Anti-Human CD31 (PECAM1) (Clone MGP7-11F10d) – Purified No Carrier Protein

N/A

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

MGP7-11F10d activity is directed against human PECAM1 (CD31), specifically the peptide sequence DQNFVILEFPVEEQDR.

PECAM1 was the first immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor to be identified in platelets and acts as a negative regulator of platelet activation¹. Platelet activation from a resting state has broad implications for many pathophysiological processes, including anthogenesis, angiogenesis, inflammation, wound repair, and cancer metastasis. PECAM1 inhibits platelet activation and thrombosis at sites of vascular injury by attenuating immunoreceptor tyrosine-based activation motif (ITAM)-containing receptor complex GPVI-FcR γ-chain signaling and by acting as a positive regulator of α_IIb β₃-mediated outside-in signaling. PECAM1, like all ITIM-containing receptors, belongs to the immunoglobulin receptor superfamily.

PECAM1 also functions as a cell adhesion molecule and is capable of mediating calcium- dependent heterophilic aggregation². Additionally, PECAM1 is expressed at cell-cell borders in the endocardial cells of the developing murine heart³. Because of its distribution pattern, PECAM1 is a target molecule for the delivery of antithrombotic agents^4,5,6,7. Research is being conducted into the ability of PECAM1 to deliver drugs to the endothelium.

MGP7-11F10d was generated against human PECAM1 using mouse as the host species⁸. MGP7-11F10d targets the peptide sequence DQNFVILEFPVEEQDR and was developed for use in immuno-MRM assays.

PECAM1 is expressed on the majority of nonerythroid hematopoietic cells, including platelets, monocytes, neutrophils, T cells, and B cell subsets as well as on vascular endothelium and the endocardial cells of developing heart tissue.

PECAM1 synthetic peptide BDKRB2

1 Coxon CH, Geer MJ, Senis YA. Blood. 129(26):3407-3418. 2017.
2 DeLisser HM, Yan HC, Newman PJ, et al. J Biol Chem. 268(21):16037-16046. 1993.
3 Baldwin HS, Shen HM, Yan HC, et al. Development. 120(9):2539-2553. 1994.
4 Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I, et al. Proc Natl Acad Sci U S A. 96(5):2379-2384. 1999.
5 Scherpereel A, Wiewrodt R, Christofidou-Solomidou M, et al. FASEB J. 15(2):416-426. 2001.
6 Ding BS, Gottstein C, Grunow A, et al. Blood. 106(13):4191-4198. 2005.
7 Chacko AM, Nayak M, Greineder CF, et al. PLoS One. 7(4):e34958. 2012.
8https://research.fredhutch.org/content/dam/stripe/paulovich/files/PaulovichLab_Mab_AvailableForImmuno-MRM_11092020.pdf